INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 08/02/22
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock CollapsesInvestors Business Daily • 08/01/22
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating CoverageBenzinga • 07/18/22
Have $1,000 to Invest? 2 Stocks to Buy Right Now That Could Help Make You a FortuneThe Motley Fool • 07/05/22
Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous TransplantGlobeNewsWire • 06/27/22
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual MeetingGlobeNewsWire • 05/02/22
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease ConferenceGlobeNewsWire • 03/25/22
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare ConferenceGlobeNewsWire • 03/08/22